The first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s FDA Early Feasibility Study, according to Abiomed (Nasdaq: ABMD) (EFS). Duc Thinh Pham, MD, and Jane Wilcox, MD, of Northwestern Medicine Bluhm Cardiovascular Institute performed the initial implant.

Impella BTR, a forward flow heart pump implanted through the axillary artery and located in the left ventricle, can pump more than six liters of blood per minute. It is smaller and less intrusive than current LVADs, allowing patients with chronic heart failure to have a less invasive heart pump option for a longer period of time. The Impella BTR is designed to allow for cardiac healing or remodeling with the use of supplementary therapy.

The goal of this trial is to see if Impella BTR is safe in patients who need left ventricular hemodynamic support, as well as if it can help patients recover or transition to their next therapy. In the first research, 10 patients will be enrolled at five hospitals and will get Impella BTR support for up to 28 days in a hospital setting. Impella Connect will securely monitor patients in the cloud, allowing clinicians access to Impella BTR status data 24 hours a day, 7 days a week. The technology will be tapered and withdrawn after the study subject no longer requires hemodynamic support. Participants will be tracked for a period of 90 days.

Abiomed reports record revenue of $261 million, up 13% from the previous year.

The company’s revenue for the quarter reached $261 million, up 13% from $232 million in the prior fiscal year’s same quarter. Revenue climbed 14% in constant currency* compared to the same quarter the previous fiscal year.
Impella® heart pump product revenue for the quarter reached $249 million, up 13% from $221 million in the prior fiscal year’s same quarter.

The company’s revenue for the quarter reached $261 million, up 13% from $232 million in the prior fiscal year’s same quarter. When compared to the same quarter the previous fiscal year, revenue climbed by 14%.
Impella® heart pump product revenue for the quarter reached $249 million, up 13% from $221 million in the prior fiscal year’s same quarter.

Ref: Abiomed